A Phase 2 interventional study of QLS-111 ophthalmic solution (0.015%) and Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) in Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral and Low-Tension Glaucoma, Unspecified Eye, sponsored by Qlaris Bio, Inc.. Completed at 1 site in South Korea. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Qlaris Bio, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.
A randomized, active-controlled, multi-site, double-masked, pilot study to evaluate the safety and tolerability of QLS-111 0.015% versus Timolol maleate ophthalmic preservative free (PF) 0.5% ophthalmic solution in subjects with NTG. Primary objective is to evaluate the ocular and systemic safety and tolerability of QLS-111 0.015% compared to active control (Timolol).
Secondary objective is to evaluate the ocular hypotensive efficacy of QLS-111 0.015% with once daily evening (QPM) and twice daily (BID) dosing versus Timolol with QPM dosing.
65 studies on the registry are indexed under Low Tension Glaucoma; 9 are open to participants now.
This study's enrollment of 37 is below the median of 42 across 32 interventional studies indexed under Low Tension Glaucoma.
Browse Low Tension Glaucoma studies →Qlaris Bio, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Qlaris' investigational product, QLS-111 ophthalmic solution, 0.15%, provided in single use vials, masked, and PF.
Drug: QLS-111 ophthalmic solution (0.015%)
Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) provided in single use vials, masked.
Drug: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)
QLS-111 ophthalmic solution 0.015% applied QPM OU for 7 days followed by BID dosing OU for 7 days, to constitute a 14-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Also known as: QLS-111
Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) with BID dosing OU will be administered up to 14 days. All IP for this study will be supplied masked in PF single use vials.
Also known as: Timolol
Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs)
Ocular safety and tolerability: (AEs)
Time frame: 14 days
Clinically significant change in visual acuity
Ocular safety and tolerability: visual acuity
Time frame: 14 days
Clinically significant change in findings on slit lamp exam
Ocular safety and tolerability: dilated biomicroscopy of eye to observe clinically significant changes from baseline
Time frame: 14 days
Clinically significant change in findings on fundus exam
Ocular safety and tolerability: dilated ophthalmoscopy to observe clinically significant changes from baseline in posterior segment of eye
Time frame: 14 days
Incidence of systemic TEAEs
Systemic safety and tolerability: AEs
Time frame: 14 days
Clinically significant changes in blood pressure (BP)
Systemic safety and tolerability: vital sign, measuring systolic and diastolic blood pressure
Time frame: 14 days
Clinically significant changes in heart rate (HR)
Systemic safety and tolerability: vital signs
Time frame: 14 days
Change from baseline (CFB) of diurnal intraocular pressure (IOP) in the study eye
Ocular hypotensive efficacy: diurnal IOP CFB
Time frame: 14 days
CFB in IOP at various timepoints in the study eye
Ocular hypotensive efficacy: IOP CFB for multiple timepoints throughout the day
Time frame: 14 days
Plan to share: No
Ran from Aug 2025 to primary completion in Feb 2026, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: QLS-111
Qlaris Bio, Inc.